Investigation Of FDA Employee Misconduct Charges Returns to OIG
This article was originally published in The Tan Sheet
Executive Summary
A "stronger appearance of impartiality, integrity" will result from returning investigative authority over allegations of FDA employee misconduct to the Department of Health and Human Services Office of Inspector General, a House Energy and Commerce Committee aide says